Aktienanalyse zu Sagimet Biosciences Inc (SGMT)SGMTSagimet Biosciences Inc

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sagimet Biosciences Inc is currently a hold. The stock is priced at $8.02, which is significantly below the average analyst price target of $28, indicating potential upside. However, the RSI is at 34.92, suggesting the stock is oversold, and the recent 5-day change is -10.19%, indicating a downward trend. The main risk is the negative earnings trend, with a projected EPS of -0.33 for Q1 2026, which could lead to further price declines if not addressed.